Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
; (12): 819-824, 2015.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-279045
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To study the efficacy and safety of Chinese Childhood Leukemia Group ALL 2008 (CCLG-ALL2008) protocol combined with tyrosine kinase inhibitor (TKI, imatinib) for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in children.</p><p><b>METHODS</b>The clinical data of 53 patients aged less than 15 years when first diagnosed with Ph+ ALL between October 2008 and December 2013 were retrospectively analyzed. The patients were assigned to two groups HR (n=26) and HR+TKI (n=27). The HR group was treated with CCLG-ALL2008 protocol (for high-risk patients). The HR+TKI group was treated with imatinib in combination with CCLG-ALL2008 protocol (for high-risk patients).</p><p><b>RESULTS</b>The complete remission rate and chemotherapy induction-related mortality rate in the TKI+HR and HR groups were 100% vs 75% and 0 vs 15%, respectively. The 3-year event-free survival (EFS) rate in the HR group was (6±5)%; the 5-year EFS rate of the TKI+HR group was (52±11)%. Compared with the HR group, the TKI+HR group had no increase in the toxic responses to chemotherapy and had a decrease in the infection rate during the induction period.</p><p><b>CONCLUSIONS</b>Application of imatinib significantly improves the clinical efficacy in children with Ph+ ALL and has good safety.</p>
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
/
ODS3 - Meta 3.2 Reduzir as mortes de recém nascidos e crianças com menos de 5 anos
Problema de saúde:
Meta 3.2: Reduzir as mortes de recém nascidos e crianças com menos de 5 anos
/
Anomalias Congênitas e Cromossômicas
/
Leucemia
/
Doenças Não Transmissíveis
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Cromossomo Filadélfia
/
Mortalidade
/
Usos Terapêuticos
/
Inibidores de Proteínas Quinases
/
Tratamento Farmacológico
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Mesilato de Imatinib
/
Genética
/
Antineoplásicos
Tipo de estudo:
Guia de prática clínica
/
Estudo prognóstico
Limite:
Adolescente
/
Criança
/
Criança, pré-escolar
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Contemporary Pediatrics
Ano de publicação:
2015
Tipo de documento:
Artigo